Association of hypoxic microenvironment with the development and progression of liver diseases

Li ZhiGuo; Yang XianZhao; Li XiaoKe; Ma Xun; Wang Shan; Zhang Mei; Ye YongAn

doi:10.3969/j.issn.1001-5256.2020.08.047

Volume 36 Issue 8

Aug. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(8): 1891-1895

PDF( 1867 KB)

Association of hypoxic microenvironment with the development and progression of liver diseases

DOI: 10.3969/j.issn.1001-5256.2020.08.047

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

Research funding:

Published Date: 2020-08-20

Abstract

Abstract

Hypoxic microenvironment is a common phenomenon of liver diseases and runs through the whole process of the development and progression of liver diseases.In recent years,the research on liver fibrosis and hypoxic microenvironment of hepatocellular carcinoma has attracted more and more attention.Hypoxia-inducible factor(HIF) is the most important hypoxic stress factor found at present.This article reviews the characteristics of hypoxic microenvironment in the liver and liver diseases and further elaborates on the association of HIF overexpression with hepatocyte damage,formation of fibrosis,and malignant transformation of hepatocytes.
- liver diseases,
- hypoxic microenvironment,
- hypoxia-inducible factor

FullText(HTML)

References(53)

References

[1] CARREAU A,EL HAFNY-RAHBI B,MATEJUK A,et al. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia[J]. J Cell Mol Med,2011,15(6):1239-1253.

[2] RAPPAPORT AM. The structural and functional unit in the human liver(liver acinus)[J]. Anat Rec,1958,130(4):673-689.

[3] JUNGERMANN K,KIETZMANN T. Oxygen:Modulator of metabolic zonation and disease of the liver[J]. Hepatology,2000,31(2):255-260.

[4] ROSMORDUC O,HOUSSET C. Hypoxia:A link between fibrogenesis,angiogenesis,and carcinogenesis in liver disease[J]. Semin Liver Dis,2010,30(3):258-270.

[5] BROUGHAN TA,NAUKAM R,TAN C,et al. Effects of hepatic zonal oxygen levels on hepatocyte stress responses[J]. J Surg Res,2008,145(1):150-160.

[6] NATH B,SZABO G. Hypoxia and hypoxia inducible factors:Diverse roles in liver diseases[J]. Hepatology,2012,55(2):622-633.

[7] SNODGRASS RG,BOβM,ZEZINA E,et al. Hypoxia potentiates palmitate-induced pro-inflammatory activation of primary human macrophages[J]. J Biol Chem,2016,291(1):413-424.

[8] WILSON GK,TENNANT DA,MCKEATING JA. Hypoxia inducible factors in liver disease and hepatocellular carcinoma:Current understanding and future directions[J]. J Hepatol,2014,61(6):1397-1406.

[9] QU A,TAYLOR M,XUE X,et al. Hypoxia-inducible transcription factor 2αpromotes steatohepatitis through augmenting lipid accumulation,inflammation,and fibrosis[J]. Hepatology,2011,54(2):472-483.

[10] LEFERE S,van STEENKISTE C,VERHELST X,et al. Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease[J]. Cell Mol Life Sci,2016,73(18):3419-3431.

[11] XIANG DM,SUN W,NING BF,et al. The HLF/IL-6/STAT3feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis[J]. Gut,2018,67(9):1704-1715.

[12] FRIEDMAN SL. Mechanisms of hepatic fibrogenesis[J]. Gastroenterology,2008,134(6):1655-1669.

[13] COPPLE BL,BAI S,BURGOON LD,et al. Hypoxia-inducible factor-1αregulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis[J]. Liver Int,2011,31(2):230-244.

[14] ANKOMA-SEY V,WANG Y,DAI Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells[J]. Hepatology,2000,31(1):141-148.

[15] NOVO E,CANNITO S,ZAMARA E,et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells[J]. Am J Pathol,2007,170(6):1942-1953.

[16] TAURA K,DE MINICIS S,SEKI E,et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis[J]. Gastroenterology,2008,135(5):1729-1738.

[17] TESTONI B,LEVRERO M,ZOULIM F. Chal enges to a cure for HBV infection[J]. Semin Liver Dis,2017,37(3):231-242.

[18] ONORI P,MORINI S,FRANCHITTO A,et al. Hepatic microvascular features in experimental cirrhosis:A structural and morphometrical study in CCl4-treated rats[J]. J Hepatol,2000,33(4):555-563.

[19] HOUSSET C,ROCKEY DC,BISSELL DM. Endothelin receptors in rat liver:Lipocytes as a contractile target for endothelin 1[J].Proc Natl Acad Sci U S A,1993,90(20):9266-9270.

[20] ROCKEY DC,FOUASSIER L,CHUNG JJ,et al. Cellular localization of endothelin-1 and increased production in liver injury in the rat:Potential for autocrine and paracrine effects on stellate cells[J]. Hepatology,1998,27(2):472-480.

[21] MCKEOWN SR. Defining normoxia,physoxia and hypoxia in tumours-implications for treatment response[J]. Br J Radiol,2014,87(1035):20130676.

[22] LUO D,WANG Z,WU J,et al. The role of hypoxia inducible factor-1 in hepatocellular carcinoma[J]. Biomed Res Int,2014,2014:409272.

[23] JU C,COLGAN SP,ELTZSCHIG HK. Hypoxia-inducible factors as molecular targets for liver diseases[J]. J Mol Med(Berl),2016,94(6):613-627.

[24] YANG W,LU Z. Nuclear PKM2 regulates the Warburg effect[J]. Cell Cycle,2013,12(19):3154-3158.

[25] ZHANG TB,ZHAO Y,TONG ZX,et al. Inhibition of glucosetransporter 1(GLUT-1)expression reversed Warburg effect in gastric cancer cell MKN45[J]. Int J Clin Exp Med,2015,8(2):2423-2428.

[26] PUGH CW,RATCLIFFE PJ. Regulation of angiogenesis by hypoxia:Role of the HIF system[J]. Nat Med,2003,9(6):677-684.

[27] WANG GL,JIANG BH,RUE EA,et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2tension[J]. Proc Natl Acad Sci U S A,1995,92(12):5510-5514.

[28] LOENARZ C,COLEMAN ML,BOLEININGER A,et al. The hypoxia-inducible transcription factor pathway regulates oxygen sensing in the simplest animal,Trichoplax adhaerens[J].EMBO Rep,2011,12(1):63-70.

[29] HAHNE M,SCHUMANN P,MURSELL M,et al. Unraveling the role of hypoxia-inducible factor(HIF)-1αand HIF-2αin the adaption process of human microvascular endothelial cells(HMEC-1)to hypoxia:Redundant HIF-dependent regulation of macrophage migration inhibitory factor[J]. Microvasc Res,2018,116:34-44.

[30] GODA N,KANAI M. Hypoxia-inducible factors and their roles in energy metabolism[J]. Int J Hematol,2012,95(5):457-463.

[31] BERRA E,BENIZRI E,GINOUVS A,et al. HIF prolylhydroxylase 2 is the key oxygen sensor setting low steadystate levels of HIF-1alpha in normoxia[J]. EMBO J,2003,22(16):4082-4090.

[32] MARXSEN JH,STENGEL P,DOEGE K,et al. Hypoxia-inducible factor-1(HIF-1)promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases[J]. Biochem J,2004,381(Pt 3):761-767.

[33] LANDO D,PEET DJ,WHELAN DA,et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch[J].Science,2002,295(5556):858-861.

[34] DAYAN F,ROUX D,BRAHIMI-HORN MC,et al. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha[J].Cancer Res,2006,66(7):3688-3698.

[35] ROTH KJ,COPPLE BL. Role of hypoxia-inducible factors in the development of liver fibrosis[J]. Cell Mol Gastroenterol Hepatol,2015,1(6):589-597.

[36] LUO W,HU H,CHANG R,et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1[J]. Cell,2011,145(5):732-744.

[37] JIAO M,NAN KJ. Activation of PI3 kinase/Akt/HIF-1αpathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma[J]. Int J Oncol,2012,40(2):461-468.

[38] DEKANTY A,LAVISTA-LLANOS S,IRISARRI M,et al. The insulin-PI3K/TOR pathway induces a HIF-dependent transcriptional response in Drosophila by promoting nuclear localization of HIF-alpha/Sima[J]. J Cell Sci,2005,118(Pt 23):5431-5441.

[39] AGANI F,JIANG BH. Oxygen-independent regulation of HIF-1:Novel involvement of PI3K/AKT/m TOR pathway in cancer[J].Curr Cancer Drug Targets,2013,13(3):245-251.

[40] MORELLO E,SUTTI S,FOGLIA B,et al. Hypoxia-inducible factor 2αdrives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein[J].Hepatology,2018,67(6):2196-2214.

[41] JIN H,LIAN N,BIAN M,et al. Oroxylin A prevents alcohol-induced hepatic steatosis through inhibition of hypoxia inducible factor 1alpha[J]. Chem Biol Interact,2018,285:14-20.

[42] ZHANG J,ZHANG Q,LOU Y,et al. Hypoxia-inducible factor-1α/interleukin-1βsignaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment[J]. Hepatology,2018,67(5):1872-1889.

[43] FRIEDMAN SL. Liver fibrosis-from bench to bedside[J]. J Hepatol,2003,38(Suppl 1):s38-s53.

[44] MOON JO,WELCH TP,GONZALEZ FJ,et al. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice[J]. Am J Physiol Gastrointest Liver Physiol,2009,296(3):g582-g592.

[45] ZHOU D,ZHANG LT,LI JF,et al. Mechanism of action of hypoxia-inducible factor 1αin the development and progression of liver fibrosis[J]. J Clin Hepatol,2019,35(7):1604-1607.(in Chinese)周丹，张立婷，李俊峰，等．缺氧诱导因子1α在肝纤维化发生发展中的作用机制[J]．临床肝胆病杂志，2019,35(7):1604-1607.

[46] NOVO E,POVERO D,BUSLETTA C,et al. The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells[J]. J Pathol,2012,226(4):588-597.

[47] LIU X,HUANG K,NIU Z,et al. Protective effect of isochlorogenic acid B on liver fibrosis in non-alcoholic steatohepatitis of mice[J]. Basic Clin Pharmacol Toxicol,2019,124(2):144-153.

[48] YAO DF,JIANG H,YAO M,et al. Quantitative analysis of hepatic hypoxia-inducible factor-1alpha and its abnormal gene expression during the formation of hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int,2009,8(4):407-413.

[49] ZHANG L,HUANG G,LI X,et al. Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxiainducible factor-1αin hepatocellular carcinoma[J]. BMC Cancer,2013,13:108.

[50] WANG M,ZHAO X,ZHU D,et al. HIF-1αpromoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment[J].J Exp Clin Cancer Res,2017,36(1):60.

[51] YANG SC,ZHANG L,LIU LP,et al. Effect of hypoxia-inducible factor 2αon chemoresistance of hepatocel-lular carcinoma[J]. Chin J Clin Pharmacol Ther,2019,24(6):630-636.(in Chinese)杨书才，张莉，刘利平，等．缺氧诱导因子2α对肝细胞癌化疗耐药性的影响[J]．中国临床药理学与治疗学，2019,24(6):630-636.

[52] MNDEZ-BLANCO C,FONDEVILA F,GARCA-PALOMO A,et al. Sorafenib resistance in hepatocarcinoma:Role of hypoxia-inducible factors[J]. Exp Mol Med,2018,50(10):1-9.

[53] WU Q,ZHOU W,YIN S,et al. Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer[J]. Hepatology,2019,70(1):198-214.

Relative Articles

[1]	Peng JIANG, Shupeng WANG, Yahui LIU. A case of portal biliopathy[J]. Journal of Clinical Hepatology, 2022, 38(2): 430-432. doi: 10.3969/j.issn.1001-5256.2022.02.034
[2]	Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis(2020,Shanghai)[J]. Journal of Clinical Hepatology, 2020, 36(12): 2667-2674. doi: 10.3969/j.issn.1001-5256.2020.12.007
[3]	Hu MuRen, Ge BuJun. Source of portal vein tumor thrombosis and advances in its diagnosis and treatment[J]. Journal of Clinical Hepatology, 2018, 34(10): 2069-2075. doi: 10.3969/j.issn.1001-5256.2018.10.006
[4]	Yan Xin, Song XinYue, Dong HongJing, Yan Qi, Zhao YouYou, Jin JingLan. Acute extensive portal vein thrombosis with pulmonary embolism: a case report[J]. Journal of Clinical Hepatology, 2018, 34(4): 845-847. doi: 10.3969/j.issn.1001-5256.2018.04.031
[5]	Yang YuanYuan, Wang XiaoYan. Mechanisms of the development and progression of portal vein thrombosis[J]. Journal of Clinical Hepatology, 2018, 34(10): 2063-2068. doi: 10.3969/j.issn.1001-5256.2018.10.005
[6]	Zhang Ying, Liu QingYan, Li ZhiWei. Surgical diagnosis and treatment of portal vein thrombosis[J]. Journal of Clinical Hepatology, 2018, 34(10): 2058-2062. doi: 10.3969/j.issn.1001-5256.2018.10.004
[7]	Ma JingQin, Luo JianJun. Interventional treatment of portal vein thrombosis[J]. Journal of Clinical Hepatology, 2018, 34(10): 2053-2057. doi: 10.3969/j.issn.1001-5256.2018.10.003
[8]	Zhang Yu, Liu FuQuan. Treatment of portal vein thrombosis: Selection of anticoagulants[J]. Journal of Clinical Hepatology, 2018, 34(10): 2047-2052. doi: 10.3969/j.issn.1001-5256.2018.10.002
[9]	Zhou RenHua, Li Peng, Zhang YanTing, Yang Hua, Yang ShaoQi. Clinical manifestations of portal vein thrombosis and related risk factors in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(2): 275-278. doi: 10.3969/j.issn.1001-5256.2016.02.015
[10]	Ji JianFeng, Xiao QiuJin, Deng XiaoLi. Effect of ultrasound- guided percutaneous injection of cinobufotalin or anhydrous ethanol in treatment of portal vein tumor thrombus: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(4): 673-677. doi: 10.3969/j.issn.1001-5256.2016.04.012
[11]	Fang ZiYan, Jin Shuai, Li Gong. Efficacy and prognostic factors of intensity-modulated radiotherapy for large primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(6): 886-890. doi: 10.3969/j.issn.1001-5256.2015.06.014
[12]	Zhang YuHuan, Jian ZhiYuan, Gao Yi, Zhu YanZhi. Prognostic impact of portal vein immunochemotherapy in patients after resection of primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(11): 1186-1189. doi: 10.3969/j.issn.1001-5256.2014.11.024
[13]	Zhou YuanYuan, Zhang SiXing, Zheng QingPing, Shi ChengLiang, Luo ZhanXiong, Li Jing, Yu Bin, Li ZhongHua. Dosimetric comparison of 3DCRT and IMRT in treatment of primary hepatocellular carcinoma with portal vein tumor thrombus[J]. Journal of Clinical Hepatology, 2014, 30(3): 245-248. doi: 10.3969/j.issn.1001-5256.2014.03.012
[14]	Chen Kai, Yang HongJi. Current perspectives on preoperative diagnosis and surgical management of portal vein thrombosis in patients requiring liver transplantation[J]. Journal of Clinical Hepatology, 2013, 29(4): 314-318.
[15]	Jiang Yi, Lyu LiZhi, Chen ShaoHua, Hu HaiZhang, Zhang XiaoJin, Cai QiuCheng, Yang Fang. Portal vein arterialization in liver transplantation: A report of clinical applications[J]. Journal of Clinical Hepatology, 2012, 28(9): 704-705.
[16]	Li JingYu, Xu LiYang, Zhang Qiang, Liu Ming. Interventional diagnosis and therapy of portal hypertension resulting from hepatic vascular abnormalities[J]. Journal of Clinical Hepatology, 2011, 27(6): 643-646.
[17]	Sun WenJing, Chen DongFeng. Probe into the pathogenesis and control methods of thrombopoiesis in portal system associated with pancreatitis[J]. Journal of Clinical Hepatology, 2010, 26(5): 484-486+492.
[18]	Wang BingLiang, Qiao NaiChun, Chen LaiRong, Sun Wei. Spiral CT in the diagnosis of liver cancer complicated with portal vein cavernous degeneration and its significance in interventional therapy [J]. Journal of Clinical Hepatology, 2010, 26(5): 540-542.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1277) PDF downloads(227)

Association of hypoxic microenvironment with the development and progression of liver diseases

DOI: 10.3969/j.issn.1001-5256.2020.08.047

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Association of hypoxic microenvironment with the development and progression of liver diseases

DOI: 10.3969/j.issn.1001-5256.2020.08.047

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content